A carregar...
Publicação
Treatment variations in cerebral venous thrombosis : an international survey
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| Artigo | 231.97 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Introduction
A variety of therapies are available to treat cerebral venous
thrombosis (CVT), but evidence supporting the efficacy of most
therapies is scarce. Heparin is considered the primary therapy [1] ,
but there is no consensus whether to use unfractionated heparin
(UFH) or low-molecular-weight heparin (LMWH). The ‘European
Federation of Neurological Societies’ (EFNS) guideline recommends
LMWH because of practical advantages and based upon
data from randomized trials in leg-vein thrombosis [2] . In the
‘International Study on Cerebral Vein and Dural Sinus Thrombosis’
(ISCVT), however, UFH was used in the majority of patients
[3] . Endovascular thrombolysis is generally reserved for severe
cases, but no randomized trials have been performed [4] . The use
of prophylactic anti-epileptic drugs (AED) in CVT is controversial
[5, 6] .
We hypothesized that considerable variations in treatment for
CVT may exist among physicians. The aim of the present study is
to determine how physicians worldwide treat CVT, using an online
survey that was distributed among physicians with an interest
in CVT.
Descrição
Palavras-chave
Venous Thrombosis Cerebral Anticoagulants
Contexto Educativo
Citação
Cerebrovasc Dis 2011;32:298–300